查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1397035

迷幻藥市場：按藥物類型、應用和最終用戶分類：2023-2032 年全球機會分析和產業預測

Psychedelic Drugs Market By Drug Type (Ketamine, Psilocybin, Others), By Application (Mental Health, Abuse Disorder, Others), By End User (Hospitals, Mental Health Center, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 230 Pages | 商品交期: 2-3個工作天內

價格

2022年迷幻藥物市值為7.523億美元，預計到2032年將達到26.141億美元，2023年至2032年的年複合成長率為13.4%。

致幻劑，也稱為致幻劑，是一種能顯著改變個體的感知、思想和情緒的物質。迷幻藥以其引起意識狀態改變的能力而聞名，其特徵通常是生動的感官體驗、不尋常的想法以及與世界的高度連結感。著名的迷幻藥包括LSD（麥角醯二乙胺）、裸蓋菇素、麥司卡林和DMT（二甲基色胺）。這些物質主要透過影響大腦中的血清素受體發揮作用，在情緒調節和感知中發揮重要作用。

由於社會對迷幻藥的接受度不斷提高、迷幻藥研發投資激增以及心理健康危機數量不斷增加，迷幻藥市場預計將顯著成長。近年來，社會對迷幻藥態度的改變已成為迷幻藥市場的主要促進因素。致幻劑以前被污名化，並且經常與反文化運動和非法活動聯繫在一起，但現在社會觀念已經發生了重大轉變。根據《美國美國科學院院刊》(PNAS) 雜誌 2020 年的一份報告，過去的研究表明，使用迷幻物質，如麥角醯二乙胺 (LSD) 和裸蓋菇素，據報道有人建議，它可能對情緒和社會連結感產生正面影響。

科學檢驗加上不斷變化的文化規範，導致人們重新評估迷幻藥，使其不僅僅是娛樂物質。此外，醫療保健專業人士、企業家甚至名人等各個領域有影響力人士的高調認可，在重塑迷幻藥敘事方面發揮了關鍵作用。因此，越來越多的政府和監管機構正在重新考慮其政策，一些司法管轄區正在將用於醫療甚至娛樂用途的致幻物質合法化甚至合法化。因此，社會對迷幻藥的接受度不斷提高預計將推動市場成長。

此外，迷幻藥物市場的研發（R＆D）活動投資顯著激增，成為市場成長和轉型的關鍵驅動力。隨著醫學界和科學界越來越認知到迷幻藥的治療潛力，特別是在治療憂鬱症、焦慮症和創傷後壓力症候群等精神疾病方面，迷幻藥的投資激增。有些事情正在發生。

有希望的臨床試驗和研究顯示了裸蓋菇素和 3,4-亞甲基二氧基甲基苯丙胺等物質的有效性，從而引發了人們對進一步研究的興趣和資金的增加。例如，2023年2月，開發創傷後壓力症候群（PTSD）等神經精神疾病治療方法的生物技術公司Transcend Therapeutics宣佈在A輪資金籌措中資金籌措了4000萬美元，該輪融資已經完成。這筆資金籌措將使 Transcend 能夠開始多項臨床試驗，包括下一代精神活性化合物的 II 期試驗。截至 2023 年 2 月，Transcend 已籌集近 4,200 萬美元。因此，增加對迷幻藥物研發的投資預計將對迷幻藥物市場的成長做出重大貢獻。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 加大迷幻藥研發投入。
      • 社會對致幻劑的接受程度提高。
      • 精神疾病盛行率上升。
    • 抑制因素
      • 關於迷幻藥使用的安全性問題。
    • 機會
      • 心理健康意識不斷增強

第4章致幻劑市場：依藥物類型

  • 概述
  • 氯胺酮
  • 裸蓋菇素
  • 其他

第5章致幻劑市場：依應用分類

  • 概述
  • 精神健康
  • 受虐障礙
  • 其他

第6章致幻劑市場：依最終用戶分類

  • 概述
  • 醫院
  • 心理健康中心
  • 其他

第7章致幻劑市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 澳洲
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 南非
    • 其他

第8章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Numinus Wellness Inc
  • Enveric Biosciences
  • Field Trip Health
  • Johnson & Johnson（J&J）
  • Havn Life
  • PharmaTher
  • Psyched Wellness
  • Apex Labs
  • Ceruvia Lifesciences
  • Braxia Scientific
Product Code: A12068

The Psychedelic Drugs Market was valued for $752.30 million in 2022 and is estimated to reach $2,614.10 million by 2032, exhibiting a CAGR of 13.4% from 2023 to 2032.

Psychedelic drugs, also known as hallucinogens, are a class of substances that can profoundly alter an individual's perception, thoughts, and feelings. Psychedelic drugs are renowned for their ability to induce altered states of consciousness, often characterized by vivid sensory experiences, unusual thoughts, and a heightened sense of connection to the world. Some well-known psychedelics include LSD (lysergic acid diethylamide), psilocybin, mescaline, and DMT (dimethyltryptamine). These substances primarily work by affecting the brain's serotonin receptors, which play a crucial role in mood regulation and perception.

The psychedelic drugs market is expected to register significant growth owing to increasing social acceptance toward psychedelics, surge in investment in the research and development of psychedelic drugs, and rise in mental health crisis. The shifting societal attitude toward psychedelics has emerged as a major driver for the psychedelic drugs market in recent years. Psychedelics were previously stigmatized and largely associated with counterculture movements and illegal activities, but psychedelics are now undergoing a significant transformation in public perception. According to 2020 report by Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS), it was reported that past research suggests that use of psychedelic substances such as Lysergic acid diethylamide (LSD) or psilocybin may have positive effects on mood and feelings of social connectedness.

The scientific validation, coupled with changing cultural norms, has led to a reevaluation of psychedelics as more than just recreational substances. Moreover, high-profile endorsements from influential figures in various fields, including healthcare professionals, entrepreneurs, and even celebrities, have played a pivotal role in reshaping the narrative surrounding psychedelics. As a result, an increasing number of governments and regulatory bodies are revisiting their policies, decriminalizing or legalizing psychedelic substances for medical and even recreational use in some regions. Thus, the rise in social acceptance toward psychedelics is expected to drive the growth of the market.

Furthermore, the psychedelic drugs market has witnessed a remarkable surge in investment in research and development (R&D) activities, emerging as a major driver for growth and transformation of the market. The surge in investment in psychedelic drugs can be attributed to growing recognition within the medical and scientific communities of the therapeutic potential of psychedelics, particularly in the treatment of mental health disorders such as depression, anxiety, and post-traumatic stress disorder.

Promising clinical trials and studies have showcased the efficacy of substances like psilocybin and 3,4-Methylenedioxymethamphetamine, prompting increased interest and funding for further exploration. For instance, in February 2023, Transcend Therapeutics, a biotechnology company that develops medicines to treat neuropsychiatric diseases, including post-traumatic stress disorder (PTSD), announced that it closed its Series A funding round of $40 million. The funding round will enable Transcend to launch multiple clinical trials, including a phase II study, with its next-generation psychoactive compound. Transcend has raised nearly $42 million as of February 2023. Thus the rise in the investment in research and development of psychedelic drugs is expected to significantly contribute in the growth of the psychedelic drugs market.

In addition, the rise in the mental health crisis has emerged as a major driver for the psychedelic drugs market, signaling a paradigm shift in the way society perceives and addresses mental health disorders. In recent years, the global burden of mental health conditions, including depression, anxiety, post-traumatic stress disorder (PTSD), and addiction, has reached unprecedented levels. For instance, according to World Health Organization, a specialized agency of the United Nations responsible for international public health, as of March 2023, an estimated 3.8% of the population experience depression.

Conventional treatments such as antidepressants and therapy have not always been effective for everyone, leading to a growing demand for alternative approaches. Psychedelic substances, including psilocybin (found in magic mushrooms) and 3,4-Methylenedioxymethamphetamine (commonly known as ecstasy), have garnered significant attention for their potential to offer breakthrough therapies. According to 2023 report by National Library of Medicine, world's largest biomedical library and a leader in research in computational health informatics, some types of psychedelic drugs, such as psilocybin and 3,4-Methylenedioxymethamphetamine (ecstasy), have shown promise as therapies for treatment-resistant depression and post-traumatic stress disorder.

Thus, the rise in mental health crisis and emergence of psychedelic drugs as promising treatment for depression, anxiety, and post-traumatic stress disorder are expected to drive the growth of the psychedelic drugs market. However, safety concerns represent a significant restraint on the growth of the psychedelic drugs market. While there is a growing body of research suggesting the therapeutic potential of psychedelics, there are also inherent risks associated with their use. One of the primary concerns is the potential for adverse psychological reactions, which can include intense anxiety, paranoia, or even hallucinations that may lead to dangerous behavior.

Moreover, the use of psychedelics in unsupervised or recreational settings can significantly increase the risk of harm, as individuals may not be adequately prepared or have the necessary support to navigate the often intense and unpredictable experiences induced by these substances. The psychedelic drugs market is segmented on the basis of drug type, application, end user, and region. By drug type, the market is categorized into ketamine, psilocybin, and other drug types.

As per application, the market is categorized into mental health, abuse disorders, and other applications. On the basis of end user, the market is categorized into hospitals, mental health center, and other. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

Major key players that operate in the global psychedelic drugs market are Johnson & Johnson, Numinus, Field Trip Health, Enveric Biosciences, Havn Life, PharmaTher, Psyched Wellness, Ceruvia Lifesciences, Apex Labs, and Braxia Scientific

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the psychedelic drugs market analysis from 2022 to 2032 to identify the prevailing psychedelic drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the psychedelic drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global psychedelic drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Application

  • Mental Health
  • Abuse Disorder
  • Others

By End User

  • Hospitals
  • Mental Health Center
  • Others

By Drug Type

  • Ketamine
  • Psilocybin
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Apex Labs
    • Havn Life
    • Numinus Wellness Inc
    • Field Trip Health
    • PharmaTher
    • Johnson & Johnson (J&J)
    • Ceruvia Lifesciences
    • Psyched Wellness
    • Enveric Biosciences
    • Braxia Scientific

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in investment for the research and development of psychedelic drugs.
      • 3.4.1.2. Increased social acceptance of psychedelic drugs.
      • 3.4.1.3. Rise in prevalence of mental illness.
    • 3.4.2. Restraints
      • 3.4.2.1. Safety concerns regarding the use of psychedelic drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in awareness about mental health

CHAPTER 4: PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Ketamine
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Psilocybin
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: PSYCHEDELIC DRUGS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Mental Health
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Abuse Disorder
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: PSYCHEDELIC DRUGS MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Mental Health Center
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: PSYCHEDELIC DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Drug Type
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Drug Type
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Drug Type
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Drug Type
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Drug Type
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Drug Type
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Drug Type
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Drug Type
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Drug Type
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Drug Type
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Drug Type
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Drug Type
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. Market size and forecast, by Drug Type
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. Japan
      • 7.4.5.2.1. Market size and forecast, by Drug Type
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Market size and forecast, by Drug Type
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Rest of Asia-Pacific
      • 7.4.5.4.1. Market size and forecast, by Drug Type
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Drug Type
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Drug Type
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. South Africa
      • 7.5.5.2.1. Market size and forecast, by Drug Type
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. Rest of LAMEA
      • 7.5.5.3.1. Market size and forecast, by Drug Type
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Numinus Wellness Inc
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Enveric Biosciences
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
  • 9.3. Field Trip Health
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
  • 9.4. Johnson & Johnson (J&J)
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Havn Life
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. PharmaTher
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Key strategic moves and developments
  • 9.7. Psyched Wellness
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Key strategic moves and developments
  • 9.8. Apex Labs
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
  • 9.9. Ceruvia Lifesciences
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
  • 9.10. Braxia Scientific
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 02. PSYCHEDELIC DRUGS MARKET FOR KETAMINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. PSYCHEDELIC DRUGS MARKET FOR PSILOCYBIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 06. PSYCHEDELIC DRUGS MARKET FOR MENTAL HEALTH, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. PSYCHEDELIC DRUGS MARKET FOR ABUSE DISORDER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 10. PSYCHEDELIC DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. PSYCHEDELIC DRUGS MARKET FOR MENTAL HEALTH CENTER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. PSYCHEDELIC DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. CANADA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. UK PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. UK PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. ITALY PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. CHINA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 54. CHINA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. CHINA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 60. AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. LAMEA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 66. LAMEA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. LAMEA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. LAMEA PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 69. BRAZIL PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 70. BRAZIL PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. BRAZIL PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 73. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 74. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 75. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 76. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. NUMINUS WELLNESS INC: KEY EXECUTIVES
  • TABLE 79. NUMINUS WELLNESS INC: COMPANY SNAPSHOT
  • TABLE 80. NUMINUS WELLNESS INC: PRODUCT SEGMENTS
  • TABLE 81. NUMINUS WELLNESS INC: PRODUCT PORTFOLIO
  • TABLE 82. ENVERIC BIOSCIENCES: KEY EXECUTIVES
  • TABLE 83. ENVERIC BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 84. ENVERIC BIOSCIENCES: PRODUCT SEGMENTS
  • TABLE 85. ENVERIC BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 86. FIELD TRIP HEALTH: KEY EXECUTIVES
  • TABLE 87. FIELD TRIP HEALTH: COMPANY SNAPSHOT
  • TABLE 88. FIELD TRIP HEALTH: PRODUCT SEGMENTS
  • TABLE 89. FIELD TRIP HEALTH: PRODUCT PORTFOLIO
  • TABLE 90. JOHNSON & JOHNSON (J&J): KEY EXECUTIVES
  • TABLE 91. JOHNSON & JOHNSON (J&J): COMPANY SNAPSHOT
  • TABLE 92. JOHNSON & JOHNSON (J&J): PRODUCT SEGMENTS
  • TABLE 93. JOHNSON & JOHNSON (J&J): PRODUCT PORTFOLIO
  • TABLE 94. JOHNSON & JOHNSON (J&J): KEY STRATERGIES
  • TABLE 95. HAVN LIFE: KEY EXECUTIVES
  • TABLE 96. HAVN LIFE: COMPANY SNAPSHOT
  • TABLE 97. HAVN LIFE: PRODUCT SEGMENTS
  • TABLE 98. HAVN LIFE: PRODUCT PORTFOLIO
  • TABLE 99. HAVN LIFE: KEY STRATERGIES
  • TABLE 100. PHARMATHER: KEY EXECUTIVES
  • TABLE 101. PHARMATHER: COMPANY SNAPSHOT
  • TABLE 102. PHARMATHER: PRODUCT SEGMENTS
  • TABLE 103. PHARMATHER: PRODUCT PORTFOLIO
  • TABLE 104. PHARMATHER: KEY STRATERGIES
  • TABLE 105. PSYCHED WELLNESS: KEY EXECUTIVES
  • TABLE 106. PSYCHED WELLNESS: COMPANY SNAPSHOT
  • TABLE 107. PSYCHED WELLNESS: PRODUCT SEGMENTS
  • TABLE 108. PSYCHED WELLNESS: PRODUCT PORTFOLIO
  • TABLE 109. PSYCHED WELLNESS: KEY STRATERGIES
  • TABLE 110. APEX LABS: KEY EXECUTIVES
  • TABLE 111. APEX LABS: COMPANY SNAPSHOT
  • TABLE 112. APEX LABS: PRODUCT SEGMENTS
  • TABLE 113. APEX LABS: PRODUCT PORTFOLIO
  • TABLE 114. CERUVIA LIFESCIENCES: KEY EXECUTIVES
  • TABLE 115. CERUVIA LIFESCIENCES: COMPANY SNAPSHOT
  • TABLE 116. CERUVIA LIFESCIENCES: PRODUCT SEGMENTS
  • TABLE 117. CERUVIA LIFESCIENCES: PRODUCT PORTFOLIO
  • TABLE 118. BRAXIA SCIENTIFIC: KEY EXECUTIVES
  • TABLE 119. BRAXIA SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 120. BRAXIA SCIENTIFIC: PRODUCT SEGMENTS
  • TABLE 121. BRAXIA SCIENTIFIC: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. PSYCHEDELIC DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PSYCHEDELIC DRUGS MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN PSYCHEDELIC DRUGS MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN PSYCHEDELIC DRUGS MARKET (2023-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL PSYCHEDELIC DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR KETAMINE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR PSILOCYBIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR MENTAL HEALTH, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR ABUSE DISORDER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. PSYCHEDELIC DRUGS MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR MENTAL HEALTH CENTER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. PSYCHEDELIC DRUGS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 24. U.S. PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CHINA PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. JAPAN PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. AUSTRALIA PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. BRAZIL PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 44. COMPETITIVE DASHBOARD
  • FIGURE 45. COMPETITIVE HEATMAP: PSYCHEDELIC DRUGS MARKET
  • FIGURE 46. TOP PLAYER POSITIONING, 2022
  • FIGURE 47. NUMINUS WELLNESS INC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 48. NUMINUS WELLNESS INC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. NUMINUS WELLNESS INC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. BRAXIA SCIENTIFIC: NET REVENUE, 2021-2022 ($MILLION)